No Aspirin for primary prevention of CVD in adults 60 years or older, says USPSTF
USA: People aged 60 or older who do not already have heart disease should not start taking aspirin, according to the US Preventive Services Task Force (USPSTF). With an update to its 2016 recommendation, the USPSTF has finalized its tougher stance on aspirin use for the primary prevention of cardiovascular disease.
Additionally, the recommendation statement, published in the Journal of the American Medical Association states that the decision to initiate aspirin in those between 40 and 59 should be made on a patient-to-patient basis and only if their individual 10-year risk of CVD is 10% or higher.
For updating its previous recommendations, the USPSTF commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (stroke and myocardial infarction), cardiovascular mortality, and all-cause mortality in people without a history of CVD. The systematic review also investigated the effect of aspirin use on colorectal cancer (CRC) incidence and mortality in primary CVD prevention populations, as well as the harms (particularly bleeding) associated with aspirin use. Also, the USPSTF commissioned a microsimulation modeling study to assess the net balance of benefits and harms from aspirin use for primary prevention of CVD and CRC, stratified by age, sex, and CVD risk level.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.